Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report

Figure 3

Alkaline phosphatase trend and response to radium-223. The trend in the patient’s alkaline phosphatase over the course of his disease is shown, and the alkaline phosphatase response to radium-223 is highlighted. Alkaline phosphatase was 564 U/L at the time of initiation of radium-223 and steadily improved throughout the course of radium-223. Alkaline phosphatase nadired at 144 U/L about 1 month after the 6th dose of radium-223 and then trended up again.

Back to article page